Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis

T. Yanagisawa, K. Mori, A. Matsukawa, T. Kawada, S. Katayama, E. Laukhtina, P. Rajwa, F. Quhal, B. Pradere, W. Fukuokaya, K. Iwatani, R. Pichler, JY. Teoh, M. Moschini, W. Krajewski, J. Miki, SF. Shariat, T. Kimura, European Association of...

. 2025 ; 74 (3) : 76. [pub] 20250201

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, systematický přehled, metaanalýza, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010008

Recent phase 3 randomized controlled trials (RCTs) demonstrate the promising impact of immune checkpoint inhibitor (ICI)-based combination therapies on locally advanced or metastatic urothelial carcinoma (UC). However, comparative data on the efficacy and toxicity of different ICI-based combinations are lacking. This study aims to compare the efficacy of first-line ICI-based combination therapies for locally advanced or metastatic UC using phase 3 RCT data. In November 2023, three databases were searched for RCTs evaluating oncological outcomes in patients with locally advanced or metastatic UC who were treated with first-line ICI-based combination therapies. Network meta-analysis (NMA) was conducted to compare outcomes, including overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), complete response rates (CRRs), and treatment-related adverse events (TRAEs). Subgroup analyses were based on PD-L1 status and cisplatin eligibility. The NMA included five RCTs. Enfortumab vedotin (EV) + pembrolizumab ranked the highest for improving OS (100%), PFS (100%), ORR (96%), and CRR (96%), followed by nivolumab + chemotherapy. EV + pembrolizumab combination superiority held across PD-L1 status and cisplatin eligibility. In patients who are cisplatin-eligible, EV + pembrolizumab significantly improved OS (HR: 0.68, 95%CI 0.47-0.99) and PFS (HR: 0.67, 95%CI 0.49-0.92) compared to nivolumab + chemotherapy. Durvalumab + tremelimumab was the safest combination for severe TRAEs, and EV + pembrolizumab ranked second. Our analyses support EV + pembrolizumab combination as a first-line treatment for locally advanced or metastatic UC. Thus, EV + pembrolizumab may become a guideline-changing standard treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010008
003      
CZ-PrNML
005      
20250429134529.0
007      
ta
008      
250415s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00262-024-03910-3 $2 doi
035    __
$a (PubMed)39891702
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
245    10
$a Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis / $c T. Yanagisawa, K. Mori, A. Matsukawa, T. Kawada, S. Katayama, E. Laukhtina, P. Rajwa, F. Quhal, B. Pradere, W. Fukuokaya, K. Iwatani, R. Pichler, JY. Teoh, M. Moschini, W. Krajewski, J. Miki, SF. Shariat, T. Kimura, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
520    9_
$a Recent phase 3 randomized controlled trials (RCTs) demonstrate the promising impact of immune checkpoint inhibitor (ICI)-based combination therapies on locally advanced or metastatic urothelial carcinoma (UC). However, comparative data on the efficacy and toxicity of different ICI-based combinations are lacking. This study aims to compare the efficacy of first-line ICI-based combination therapies for locally advanced or metastatic UC using phase 3 RCT data. In November 2023, three databases were searched for RCTs evaluating oncological outcomes in patients with locally advanced or metastatic UC who were treated with first-line ICI-based combination therapies. Network meta-analysis (NMA) was conducted to compare outcomes, including overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), complete response rates (CRRs), and treatment-related adverse events (TRAEs). Subgroup analyses were based on PD-L1 status and cisplatin eligibility. The NMA included five RCTs. Enfortumab vedotin (EV) + pembrolizumab ranked the highest for improving OS (100%), PFS (100%), ORR (96%), and CRR (96%), followed by nivolumab + chemotherapy. EV + pembrolizumab combination superiority held across PD-L1 status and cisplatin eligibility. In patients who are cisplatin-eligible, EV + pembrolizumab significantly improved OS (HR: 0.68, 95%CI 0.47-0.99) and PFS (HR: 0.67, 95%CI 0.49-0.92) compared to nivolumab + chemotherapy. Durvalumab + tremelimumab was the safest combination for severe TRAEs, and EV + pembrolizumab ranked second. Our analyses support EV + pembrolizumab combination as a first-line treatment for locally advanced or metastatic UC. Thus, EV + pembrolizumab may become a guideline-changing standard treatment.
650    _2
$a lidé $7 D006801
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    12
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    12
$a síťová metaanalýza $7 D000071076
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a karcinom z přechodných buněk $x farmakoterapie $x mortalita $x patologie $7 D002295
650    _2
$a urologické nádory $x farmakoterapie $x mortalita $x patologie $7 D014571
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a nádory močového měchýře $x farmakoterapie $x patologie $x mortalita $7 D001749
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a monoklonální protilátky $7 D000911
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria. morikeiichiro29@gmail.com $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. morikeiichiro29@gmail.com
700    1_
$a Matsukawa, Akihiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Fukuokaya, Wataru $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Iwatani, Kosuke $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Pichler, Renate $u Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
700    1_
$a Moschini, Marco $u Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy
700    1_
$a Krajewski, Wojciech $u Department of Minimally Invasive and Robotic Urology, Wrocław Medical University, Wrocław, Poland
700    1_
$a Miki, Jun $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
710    2_
$a European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
773    0_
$w MED00001041 $t Cancer immunology and immunotherapy $x 1432-0851 $g Roč. 74, č. 3 (2025), s. 76
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39891702 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134524 $b ABA008
999    __
$a ok $b bmc $g 2311399 $s 1247089
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 74 $c 3 $d 76 $e 20250201 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
LZP    __
$a Pubmed-20250415
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace